Victory Capital Management Inc. Makes New Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Key Points

• Victory Capital Management Inc. has acquired a new position in Kiniksa Pharmaceuticals, purchasing 53,317 shares valued at approximately $1.18 million, representing 0.07% of the company.
• Wall Street analysts are optimistic about Kiniksa Pharmaceuticals, with price targets increasing; Wells Fargo raised its target from $30 to $42 and Jefferies from $45 to $54, reflecting a consensus "Buy" rating.
• Insider transactions indicate significant activity, with CEO Sanj K. Patel selling 62,116 shares worth about $1.7 million, reducing his ownership in the company by 39.12%.

Victory Capital Management Inc. purchased a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 53,317 shares of the company's stock, valued at approximately $1,184,000. Victory Capital Management Inc. owned approximately 0.07% of Kiniksa Pharmaceuticals International as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares during the period. Asset Management One Co. Ltd. acquired a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $41,000. Wealthquest Corp acquired a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $42,000. Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth about $61,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth about $158,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Eben Tessari sold 18,900 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $28.72, for a total transaction of $542,808.00. Following the sale, the chief operating officer owned 49,163 shares in the company, valued at approximately $1,411,961.36. This trade represents a 27.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark Ragosa sold 18,299 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $28.80, for a total transaction of $527,011.20. Following the sale, the chief financial officer owned 27,009 shares in the company, valued at approximately $777,859.20. This trade represents a 40.39% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 320,981 shares of company stock worth $9,189,467 in the last three months. 53.48% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have weighed in on KNSA. Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wells Fargo & Company upped their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research report on Sunday, July 6th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Trading Up 5.7%

Shares of KNSA stock traded up $1.72 during trading hours on Friday, hitting $31.98. The company's stock had a trading volume of 1,072,119 shares, compared to its average volume of 698,224. The business has a fifty day moving average of $28.28 and a 200-day moving average of $23.97. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of 799.70 and a beta of 0.05. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.82 and a twelve month high of $32.15.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. On average, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.